Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Priority Brief

Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer

Katarzyna Urbanska, Caitlin Stashwick, Mathilde Poussin and Daniel J. Powell Jr
Katarzyna Urbanska
1Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caitlin Stashwick
1Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathilde Poussin
1Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel J. Powell Jr
1Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
2Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: poda@mail.med.upenn.edu
DOI: 10.1158/2326-6066.CIR-15-0047 Published October 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Anti–FSHR-IR construction and expression in primary human T cells. A, schematic of lentiviral anti–FSHR-IR vectors containing an anti-FSHR peptide linked to intracellular signaling domains from CD3-z (IR-z) alone and in tandem with CD28 (IR-28z). Anti-FSHR constructs also encode GFP separated by a viral T2A (2A) ribosomal skip peptide. B, transgene expression in primary human T cells. Expression of anti–FSHR-IR constructs in primary human T cells was measured by GFP. TM, transmembrane domain; UNT, untransduced T cells. C, FSHR expression detected by flow cytometry using rabbit anti–FSHR-APC IgG (open histogram) and isotype control (gray). Specific mean fluorescence intensity (MFI) is shown on each plot. D, expression of human FSHR in ovarian cancer cell lines and control 293T cells determined by RT-PCR using FSHR-specific PCR primers. Controls included 293T cells and no input (H2O). RT-PCR using FSHR primers based on human sequence (NM_0) amplified the predicted 234-bp product from cDNA templates. Five-fold less PCR-amplified cDNA from CaOV434 cells was loaded relative to other lanes to avoid spillover.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Anti-FSHR T cells recognize human and mouse ovarian cancer cells expressing FSHR but not cells without the FSHR expression. A, levels of IFNγ in supernatants following overnight coculture of anti–FSHR-IR T cells with FSHR+ and FSHR− CaOV3 or FSHR− 293T target cells detected by ELISA. Cocultures were established at 1:1 E:T ratio. B, IFNγ in overnight cocultures of anti–FSHR-IR T cells with mouse FSHR+ ID8 cells or FSHR− AE17 mesothelioma cell lines. C, lack of immune recognition of human recombinant FSHR protein by anti–FSHR-IR T cells. Results are presented as mean ± SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001 (Student t test).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Anti–FSHR-IR T cells react against and lyse FSHR-expressing human and mouse cancer cells in vitro. A, cytokine secretion by anti–FSHR-redirected T cells and control GFP–transduced primary human T cells. IFNγ, IL2, MIP1α, TNFα, IL4, and IL10 secretion was detected by CBA 16 hours after tumor stimulation (data represent three independent experiments in triplicates). Results are presented as mean ± SD. Values of P < 0.01 and P < 0.05 were considered statistically significant. We observed a specific and statistically significant production of cytokines; IFNγ, IL2, MIP1α, and TNFα by anti-FSHR 33–53b-28z and anti-FSHR agonist A-28z against FSHR+ targets human CaOV3 and mouse ID8 cell lines when compared with cytokine levels in cocultures with FSHR− targets in human 293T and mouse AE17 cell lines. B, anti-FSHR+ T cells upregulate surface CD69 expression upon 24-hour exposure to FSHR-expressing targets. The FSHR+ IR T cells are identified by GFP expression. Graph, percentage of CD69-positive cells gated on the viable CD3+/GFP-positive T-cell population. C, cytotoxicity of anti-FSHR T cells. Anti-FSHR 33–53β-28z or agonist A-28z IR T-cell killing of FSHR-expressing human CaOV3 and mouse ID8, or control 293T or AE17 cells, was assessed in a 16-hour luciferase-based killing assay. T cells were cocultured with target cells expressing firefly luciferase at E:T ratios of 0:1, 1:1, or 3:1. Residual luciferase signal was determined after 16 hours. The percentage of lysis was determined by luminescence in comparison with untreated target wells. Results, mean ± SD. *, P < 0.05 was considered statistically significant.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Suppressed ovarian cancer growth in mice receiving anti–FSHR-IR T-cell treatment. A, 5 × 106 luciferase-expressing CaOV3 cells were injected s.c. into NSG mice on day 0. A total of 5 × 106 T cells were injected i.v. on days 20 and 25. Tumor growth was monitored by caliper measurement. Graphs, mean ± SEM of 5 mice per experiment. P values were calculated compared with GFP T-cell– and PBS-treated control mice. *, P < 0.05 was considered statistically significant. *, P < 0.05; **, P < 0.01. B, preferential expansion and survival of human T cells in peripheral blood of anti–FSHR-IR T-cell–treated mice, compared with control GFP T-cell and PBS-treated groups. Peripheral blood was collected 20 and 35 days after T-cell injection and absolute number of human CD3+ T cells was quantified by flow cytometry using TruCount beads and reported as total cells per microliter of blood. Bar graphs, mean ± SD for 5 mice per group. P values were determined compared with the control GFP T-cell–treated group. *, P < 0.05.

Tables

  • Figures
  • Additional Files
  • Table 1.

    FSH peptides used for anti–FSHR-IR construction

    Construct nameaFSH-derived peptidesSequencePredicted affinityPredicted cross-reactivity
    Anti-FSHR 33–53β-IRβ-Chain 33–53aaYTRDLVYKDPARPKIQKTCTF10−5 mol/LHuman/mouse
    Anti-FSHR 51–65β-IRβ-Chain 51–65aaCTFKELVYETVRVPGC10−4 mol/LHuman
    Anti-FSHR 81–95β-IRβ-Chain 81–95aaQCHCGKCDSDSTDCT10−5 mol/LHuman/mouse
    Anti-FSHR antagonist A-IRβ-Chain (87–94aa) + α-chain (25–42aa)CDSDSTDCILQCMGCCFSRAYPTPLR10−8 mol/LHuman/mouse
    Anti-FSHR agonist A-IRβ-Chain (87–94aa) + α-chain (25–42aa)CDSDSTDCILQCMGCCFSRAYPTPLRWCAGYCYCYTRD10−7 mol/LHuman/mouse
    +b (27–45aa)VKDPARP
    Anti-FSHR a+b-IRFSH (α-chain + β-chain)GenBank Gene IDs: 1081 (FSH, α subunit) + 2488 (FSH, β subunit)NAHuman/mouse
    • ↵Abbreviation: NA, not available.

      aFinal chimeric IR constructs were engineered to encode for either an intracellular CD3z (-z) or a tandem CD3z and CD28 (-28z) domain.

Additional Files

  • Figures
  • Tables
  • Supplementary Data

    • Supplementary Figure 1 - The expression of 18S used as a internal control (housekeeper). cDNA was constructed from total RNA isolated from 10e5 cells (cultured at 60-70% confluence). PCR performed using intron-spanning primers. Validation criteria included water blanks, and NO RT samples. For human 18SrRNA 5’CAGCCACCCGAGATTGAGCA3’ and Rev: 5’TAGTAGCGACGGGCGGTGTG3’ (amplicon 253bp) (Genbank:: NR_003286.2). For mouse ID8 cell line Ribosomal RNA for mouse Eukaryotic small ribosomal subunit [Genbank: NR_003278] primers Fw: 5’AGGGGAGAGCGGGTAAGAGA-3’ and Rev: 5’GGACAGGACTAGGCGGAACA3’ were used (amplicon size of 249bp).
    • Supplementary Figure Legend
PreviousNext
Back to top
Cancer Immunology Research: 3 (10)
October 2015
Volume 3, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer
Katarzyna Urbanska, Caitlin Stashwick, Mathilde Poussin and Daniel J. Powell Jr
Cancer Immunol Res October 1 2015 (3) (10) 1130-1137; DOI: 10.1158/2326-6066.CIR-15-0047

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer
Katarzyna Urbanska, Caitlin Stashwick, Mathilde Poussin and Daniel J. Powell Jr
Cancer Immunol Res October 1 2015 (3) (10) 1130-1137; DOI: 10.1158/2326-6066.CIR-15-0047
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Inducing CTLs through DLnano-vaccines to Target Cancer
  • Targeted Inhibitors Increase T-cell Activation
  • Remodeling Translation Primes T-cell Tumor Control
Show more Priority Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement